文献速递临床试验与 GCP流行病学与生物统计

密歇根遗传性肿瘤基因检测(MiGHT)研究促进癌症患者接受临床基因检测的创新方法:三臂随机对照试验研究方案

The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial.
PubMed 文献 · Trials · 2023-02-10

MiGHT研究是一项三臂随机对照试验,旨在评估两种患者层面行为干预对癌症基因检测接受率的效果。干预分别为虚拟遗传学导航员和由遗传健康教练实施的动机性访谈。研究对象为符合NCCN基因检测标准的乳腺癌、前列腺癌、子宫内膜癌、卵巢癌、结直肠癌或胰腺癌成人患者,计划招募759人,主要结局为6个月内完成胚系基因检测的比例。

要点

  • MiGHT研究比较虚拟遗传学导航员与动机性访谈两种干预对癌症基因检测接受率的效果。
  • 研究对象为符合NCCN基因检测标准的乳腺癌、前列腺癌、子宫内膜癌、卵巢癌、结直肠癌或胰腺癌成人患者。
  • 主要结局为随机分组后6个月内完成胚系基因检测的比例。

核心结论

  • 该研究针对与基因检测接受率相关的患者层面因素,检验两种干预方法,二者均可能有助于缓解遗传咨询师短缺并改善就医可及性。

研究设计与样本

  • 三臂随机对照试验,计划招募759名符合NCCN基因检测标准的癌症成人患者,随机分配至常规照护组、虚拟遗传学导航员组或动机性访谈组。
  • 参与者通过密歇根肿瘤质量联盟(MOQC)附属社区肿瘤实践招募,并使用家族健康史工具(FHHT)确定检测资格。

关键数值与推荐

  • 主要结局为6个月内完成胚系基因检测的个体比例。
  • 纳入标准为诊断为乳腺癌、前列腺癌、子宫内膜癌、卵巢癌、结直肠癌或胰腺癌且符合NCCN基因检测标准的成人。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although most cancers are sporadic, germline genetic variants are implicated in 5-10% of cancer cases. Clinical genetic testing identifies pathogenic germline genetic variants for hereditary cancers. The Michigan Genetic Hereditary Testing (MiGHT) study is a three-arm randomized clinical trial that aims to test the efficacy of two patient-level behavioral interventions on uptake of cancer genetic testing. METHODS: The two interventions being tested are (1) a virtual genetics navigator and (2) motivational interviewing by genetic health coaches. Eligible participants are adults with a diagnosis of breast, prostate, endometrial, ovarian, colorectal, or pancreatic cancer who meet the National Comprehensive Cancer Network (NCCN) criteria for genetic testing. Participants are recruited through community oncology practices affiliated with the Michigan Oncology Quality Consortium (MOQC) and have used the Family Health History Tool (FHHT) to determine testing eligibility. The recruitment goal is 759 participants, who will be randomized to usual care or to either the virtual genetics navigator or the motivational interviewing intervention arms. The primary outcome will be the proportion of individuals who complete germline genetic testing within 6 months. DISCUSSION: This study addresses patient-level factors which are associated with the uptake of genetic testing. The study will test two different intervention approaches, both of which can help address the shortage of genetic counselors and improve access to care. TRIAL REGISTRATION: This study has been approved by the Institutional Review Board of the University of Michigan Medical School (HUM00192898) and registered in ClinicalTrials.gov (NCT05162846).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gerido LH, Griggs JJ, Resnicow K, et al. The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial. Trials. 2023. PMID: 36765432. doi:10.1186/s13063-023-07125-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。